The company is pursuing a Phase 3 trial in its most exciting pipeline drug, and investors are awaiting potentially exciting ...

Viking has a market value of about $3.5 billion, leaving it room to run if it gains product approvals and then goes on to generate revenue growth. A 10x increase would result in a market cap of $35 ...

Viking Therapeutics, Inc. stock has surged nearly 1,500% since 2023, driven by the promising GLP-1/GIP receptor agonist VK-2735 for obesity. VK-2735's Phase 2 data showed weight loss comparable to ...

Viking Therapeutics' stock initially surged after positive Phase 2 data for its obesity drug, but fell after Novo Nordisk shared data on a new, oral weight loss drug. Eli Lilly and Novo Nordisk have ...

Viking Therapeutics (NASDAQ: VKTX) suffered a brutal market sell-off on Tuesday, with shares plunging over 40% in one of the biotech firm's steepest single-day drops since its initial public offering ...

Viking Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating ...

Biotech company Viking Therapeutics has emerged as a strong potential player — and deal target — in the budding weight loss drug market. Viking is just one of several companies racing to join the ...

Viking aims to enter a market that may be worth $100 billion in a few years. Patients and investors are excited about this class of drug thanks to impressive results in clinical trials and in the real ...